Cambritaxestat

N/A

Report date: 2026/02/04 11:35:25
NMEFirst In Class

Base Information

Drug NameCambritaxestat
Drug Alias NameIOA-289CRT-0273750
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitorsCell proliferation inhibitorsAngiogenesis inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCancer Research TechnologyMerck & Co
China Registration ClassN/A

Develop Information

Active CompaniesIonctura Sa
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A